To be completed at first contact meeting to document the initial economic components of the study

|  |
| --- |
| **Study title:** |
| **PI/CI:** | **CCTU Ref:** |
| **Funding stream:** | **Deadline:** | **Proposed start date:** | **Duration of grant:** |
| **Level of input required from health economist:*** A) Brief advice
* B) Co-applicant

*If (A) provide details of advice given at the end of this form. If (B) complete the rest of this form.* |

|  |  |
| --- | --- |
| **Population:** | **Intervention:** |
| **Comparator(s):***(please justify choice, e.g. common use in NHS)* | **Outcomes:** |
| **Follow-up period of study and data collection time points:** |
| **Type of economic evaluation / study:***(tick all that apply)** A) CUA
* B) CEA
* C) CBA
* D) CMA or cost analysis only

E) Other (specify\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_) | **Analytic perspectives to be analysed:***(tick all that apply)** NHS
* Public sector (NHS + social services)
* Societal (public sector + patient OOP + lost productivity
* Other (specify \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_)
 |

|  |
| --- |
| **Resource use data to be collected alongside the trial** |
| **NHS Primary Care** |
| * ‘Standard data set’ (GP/nurse contacts, surgery/telephone/home)
* Contacts with other primary care-based specialists (e.g. physio)

Specify:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_* Prescriptions
	+ All
	+ Disease specific

 State key drugs:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_* Other

Specify :\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | Data collection method* Patient questionnaire
* Research nurse review & extract from primary care record
* Mix (provide details in space below)
* Other

(provide details below) |
| **NHS Secondary Care** |
| * ‘Standard data set’

A&E, OP, DC, IP (delete as appropriate)* + All contacts
	+ Disease-specific contacts
* Other

Please provide details: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | Data collection method:* Patient questionnaire
* HES
* Research nurse review & extract from secondary care record
* Mix (provide details in space below)
* Other

(provide details below) |
| **NHS tertiary / other resource use** |
| Provide details below: | Describe how data will be collected: |
| **Social care**  |
| CSRI items:* usual living situation (e.g. home or institution)
* specialist mental health services (e.g. secure MH facility,

assessments, acute psychiatric ward / rehabilitation ward / long stay)* Day activity services (e.g. community centre, NHS and/or Local Authority)
* Community care services (e.g. case manager, community MH, learning difficulty, behaviour or older persons community team member)
* Criminal justice services
* Other

Details: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | Data collection method* Adapted CSRI
* Other

(provide details below) |
| **Patient out of pocket costs** |
| * Travel costs to hospital and/or GP
* Travel costs, other (details: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_)* Out of pocket medication costs (details: \_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_)* Other (details: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_) | Data collection method:* Patient questionnaire
* Other (Specify: e.g. receipts, outer packets of OTC drugs)
 |
| **Lost productivity** |
| * Lost productivity
 | Data collection method:* Patient questionnaire
* Other (Specify)
 |
| **Other resource use items** |
| Please specify: | Data collection method: |

|  |
| --- |
| **Outcome measures to be used in the Economic Analysis** |
| **Clinical measure(s):***(normally the primary outcome)* | **PROMS:***(generic and/or disease specific measures)* |

|  |
| --- |
| **Within-trial Analysis** |
| * Conventional incremental analysis with non-parametric bootstrap reporting ICER, CIs around increments and CEAC
* Other (please specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| **Are there any specific or potential issues the analysis will need to take into account?***(e.g. clustering)* |

|  |
| --- |
| **Decision modelling** |
| Is any decision modelling required to project within trial results to longer term costs and outcomes?* Yes
* No
 | If yes, please justify:*(e.g. RCT will only provide interim or proxy outcomes such as reduction in biochemical markers of risk)* |
| Decision model structure:* Decision tree
* Markov chain
* Microsimulation
* Other (specify:

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | Key elements model must take into account:*(e.g.future acute events such as fracture, MI, stroke)* |
| Key studies or previous models on which the model may draw:*(Note a systematic review will be conducted as part of the model development process, but it would be useful to list here any pre-existing reviews (especially Cochrane), pivotal clinical trials in the area or epidemiological studies linking interim outcomes to final outcomes).* |
| Time horizon of the model: |

|  |
| --- |
| Any other information (including details of brief advice given to PI where health economist not required as co-applicant): |